Answers are grounded in this paper and cite their sources.
Organelle-level precision can advance cancer nanomedicine beyond nonspecific intracellular delivery toward spatially defined therapeutic action. DNA nanoframeworks, nanodevices, and nanomachines are promising because their sequence, geometry, valency, and dynamic states can be programmed to integrate molecular recognition with sensing, computation, structural reconfiguration, and cargo release. However, organelle targeting is often treated as a localization problem, whereas therapeutic function demands a sequence of biological and engineering steps: systemic stability, tumor-cell recognition, cellular uptake, endosomal escape, intracellular trafficking, organelle recognition, functional localization, stimulus processing, actuation, and measurable biological response. This review differentiates DNA nanoframeworks, nanodevices, and nanomachines and evaluates their progression from molecular design to intracellular action. We summarize DNA-containing systems targeting mitochondria, lysosomes, the nucleus, endoplasmic reticulum, and Golgi apparatus, focusing on targeting ligands, trafficking routes, stimulus-responsive mechanisms, actuation, reporting, and therapeutic function. Non-DNA systems are considered only as contextual comparators relevant to DNA-device engineering. Finally, we discuss artificial intelligence and self-driving laboratories as emerging tools for sequence and structure optimization, image analysis, and closed-loop experimentation, while separating demonstrated capabilities from the still prospective goal of autonomous intracellular navigation. We also identify design rules, evidence standards, and translational barriers guiding reproducible, mechanistically validated DNA nanodevices for precision intracellular therapy.
No takes yet. Share an insight, caveat, or question.
Farooq et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: